调强放疗时代升型与降型鼻咽癌的临床特征与生存结局比较
该研究从中山大学肿瘤防治中心随机选取5194例调强放疗(IMRT)时代的升型(A型)和降型(D型)鼻咽癌患者,比较两型的临床特征与生存结局。结果显示A型占82%、D型占18%,D型患者远处转移、区域复发、疾病复发和死亡风险均显著增加,且复发后死亡风险比为1.6。多因素分析显示EBV DNA升高、乳酸脱氢酶升高、饮酒及无癌症家族史与D型发生相关。
要点
- D型鼻咽癌远处转移、区域复发、疾病复发和死亡风险均高于A型(P<0.001)。
- D型复发后死亡风险比为A型的1.6倍。
- EBV DNA升高、LDH升高、饮酒及无癌症家族史与D型发生相关。
核心结论
- 在IMRT时代,D型鼻咽癌较A型具有更强的侵袭性临床病程和更差的生存结局。
研究设计与样本
- 从中山大学肿瘤防治中心随机选取5194例接受IMRT治疗的A型和D型鼻咽癌患者进行回顾性分析。
主要发现
- A型肿瘤占82%,D型肿瘤占18%。
- D型患者远处转移、区域复发、疾病复发和死亡风险均高于A型(P<0.001)。
- D型复发后死亡风险比(HR)为1.6(对照A型)。
- 多因素分析显示EBV DNA升高、乳酸脱氢酶升高、饮酒及无癌症家族史与D型发生相关。
- A型患者年 hazard 率在初治后12–18个月达峰后下降,D型前5年趋势相似,7–8年出现小峰。
关键数值与推荐
- A型定义为以局部晚期(T3-4)为主伴早期颈淋巴结受累(N0-1)的鼻咽癌。
- D型定义为以晚期淋巴结病变(N2-3)为主伴早期局部侵犯(T1-2)的鼻咽癌。
临床怎么用
- 对D型鼻咽癌患者应警惕其更高的远处转移和复发风险,加强随访监测。
- EBV DNA升高、LDH升高、饮酒及无癌症家族史者可能更易发生D型,需关注分型评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare clinical features and survival outcomes in patients with ascending type (type A) and descending type (type D) nasopharyngeal carcinoma (NPC) in the intensity-modulated radiotherapy (IMRT) era. MATERIALS AND METHODS: A total of 5194 patients with type A and type D NPC treated at Sun Yat-sen University Cancer Center were randomly selected. Tumors that were mainly advanced local disease (T3-4 stage) with early stage cervical lymph node involvement (N0-1 stage) were determined as type A, while tumors with advanced lymph node disease (N2-3 stage) but early stage local invasion (T1-2 stage) were classified as type D NPC. Kaplan-Meier's analysis was used to evaluate survival rates, and log-rank test survival curves were used for comparison. In the multivariate analysis Cox proportional hazard models were developed. RESULTS: There was a larger proportion of type A tumors (82%) than type D tumors (18%). Compared to patients with type A tumors, those with type D tumors had increased likelihood of distant metastasis, regional recurrence, disease recurrence, and death (P < 0.001 for all), however, not for local recurrence (P < 0.001). The HR (hazard ratio) for death following recurrence of disease for type D tumors were 1.6 compared to type A tumors. Multivariate analysis revealed that elevated EBV DNA, elevated lactate dehydrogenase, alcohol consumption, and no family history of cancer attributed to the development of type D tumors. Annual hazard rate in type A patients increased, peaking at 12-18 months after initial treatment and downward thereafter. Similar trend also occurred in type D during the first 5 years following treatment. Notably, a minor peak was also observed 7-8 years post treatment. CONCLUSIONS: In the IMRT era, recurrence patterns differed across tumor types. Type D NPC had a more aggressive clinical course and worse outcomes compared with type A NPC.
引用
- Yao JJ, Qi ZY, Liu ZG, et al. Clinical features and survival outcomes between ascending and descending types of nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis. Radiother Oncol. 2019. PMID: 31102988. doi:10.1016/j.radonc.2019.04.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。